Citywire for Financial Professionals
Stay connected:

View the article online at

Scottish Mortgage takes biotech professor on board

Scottish Mortgage investment trust appoints Professor Patrick Maxwell of University of Cambridge to strengthen its understanding of genomics.

Scottish Mortgage takes biotech professor on board

Scottish Mortgage (SMT ) investment trust has appointed Cambridge University professor Patrick Maxwell, an eminent biotech expert, as a non-executive director to deepen its understanding of medical science.

Maxwell, who heads the university’s School of Clinical Medicine, holds a Wellcome Trust senior investigator award for his research on oxygen sensing and sits on a number of medical research organisations’ boards.

He was elected a fellow of the Academy of Medical Sciences in 2005 and chairs the Medical Research Council's molecular and cellular medicine board. He is currently a director of the Global Medical Excellence Cluster (Gmec) and a member of the boards of Cambridge University Health Partners (CUHP) and Cambridge University Hospitals NHS Foundation Trust.

Maxwell will take up his position on 1 April. The trust's chairman, John Scott, said: ‘Professor Maxwell's deep knowledge in many fields of medical science will be of great value to Scottish Mortgage, particularly at a time when the developing field of genomics is of increasing importance to investors.

‘The board very much looks forward to working with Patrick and I have no doubt that he will make a significant contribution to the future of Scottish Mortgage.’

The £3.2 billion trust, which is managed by James Anderson (pictured) and Tom Slater, has the second best long-term record of any global investment trust, with a total shareholder return of 159% over ten years compared to the 60% from the UK's FTSE All Share index.

That performance has been achieved with a portfolio focused on companies exploiting long-term technological and scientific change. Alongside a string of internet stocks, it also invests in biotech and medical science business, the largest of which is Illumina (ILMN.N), the US manufacturer of low-cost gene sequencing equipment, which accounts for 7.6% of the fund.

More recent performance has suffered as investors have shied from high growth investing in response to fears of a global slowdown. The shares have fallen 12% since the start of the year, the most of any global fund, and trade at a small discount of nearly 3% below net asset value, having stood at a 7.5% premium a few months ago.

1 comment so far. Why not have your say?

Steve Hayes

Mar 11, 2016 at 12:23

Boffin - oh perlease. Written by a tired hack I suppose

report this

leave a comment

Please sign in here or register here to comment. It is free to register and only takes a minute or two.

News sponsored by:

The Citywire Guide to Investment Trusts

In this guide to investment trusts, produced in association with Aberdeen Asset Management, we spoke to many of the leading experts in the field to find out more.

Watch Now

More about this:

Look up the investment trusts

  • Scottish Mortgage (Ordinary Share)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Look up the fund managers

  • James Anderson
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them


Today's articles

Tools from Citywire Money

From the Forums

+ Start a new discussion

Weekly email from The Lolly

Get simple, easy ways to make more from your money. Just enter your email address below

An error occured while subscribing your email. Please try again later.

Thank you for registering for your weekly newsletter from The Lolly.

Keep an eye out for us in your inbox, and please add to your safe senders list so we don't get junked.


IFS says taxes need to hit historic highs to save NHS

by Dylan Lobo on May 24, 2018 at 07:56

Sorry, this link is not
quite ready yet